Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05233592 · ClinicalTrials.gov registry record
Glycemic Effects of the COVID-19 Booster Vaccine in Type 1 Diabetes
A clinical trial, sponsored by Johns Hopkins University.
- Completed
- Registry status
- 21
- Enrollment target
NCT05233592: Completed study, sponsored by Johns Hopkins University.
NCT05233592 is a clinical trial that has completed, run by Johns Hopkins University. The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05233592 has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- 21 participants
- Enrollment target
Study Summary
Vaccines for COVID-19 are an essential part of combating the coronavirus pandemic. Vaccines "prime" the immune system against an invader (in this case the SARS-CoV-2 virus) by causing a temporary increased immune or inflammatory response. Inflammation can temporarily increase sugar levels and/or insulin requirements among patients with diabetes. The purpose of this study is to investigate whether the "booster" COVID-19 vaccine dose causes temporarily increased sugar levels and/or insulin dose requirements among patients with Type 1 Diabetes (T1D).
Interventions
- DEVICE CGM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2022-03-08 |
| Est. Completion | 2023-04-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05233592
The ClinicalTrials.gov registry entry for NCT05233592 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CGM is the first listed.
NCT05233592 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05233592 about?
NCT05233592 is a clinical study titled "Glycemic Effects of the COVID-19 Booster Vaccine in Type 1 Diabetes". Vaccines for COVID-19 are an essential part of combating the coronavirus pandemic. Vaccines "prime" the immune system against an invader (in this case the SARS-CoV-2 virus) by causing a temporary increased immune or inflammatory response. Inflammation can temporarily increase sugar levels and/or ins...
What is the current status of trial NCT05233592?
This trial is currently completed. The enrollment target is 21 participants. The study started on 2022-03-08. Estimated completion is 2023-04-04.
What interventions are being tested in trial NCT05233592?
The interventions under investigation include: CGM (DEVICE).
Who is sponsoring clinical trial NCT05233592?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.